

Market Announcement

19 March 2025

Opthea Limited (ASX: OPT) – Suspension from Quotation

Description

The securities of Opthea Limited ('OPT') will be suspended from quotation immediately under Listing Rule 17.2, at the request of OPT, pending the release of an announcement regarding clinical trial results.

Issued by

ASX Compliance



19 March 2025

Ms Melissa Kostopoulos
Senior Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
525 Collins Street
South Tower Level 50
Melbourne VIC 3000

By email: melissa.kostopoulos@asx.com.au / tradinghaltsmelbourne@asx.com.au

Dear Melissa

**Opthea Limited (ASX: OPT)
Request for Voluntary Suspension**

Pursuant to Listing Rule 17.2, Opthea Limited (ACN 006 340 567) (**Opthea**) requests a voluntary suspension of its quoted securities (ASX Codes: OPT, OPTOA, OPTOB) to apply from the open of trading today, Wednesday, 19 March 2025.

The voluntary suspension is requested pending a material announcement by Opthea to the market in relation to the top line results of its Phase 3 COAST (Combination OPT-302 with Aflibercept Study) clinical trial (the **COAST Results**).

In accordance with Listing Rule 17.2, Opthea provides the following information:

- the voluntary suspension is requested pending the release of an announcement by Opthea in relation to the COAST Results;
- Opthea requests that the voluntary suspension remain in place until an announcement to the market by Opthea in relation to the COAST Results or the commencement of trading on Monday, 24 March 2025; and
- Opthea is not aware of any reason why the voluntary suspension should not be granted or of any other information necessary to inform the market regarding the voluntary suspension.

Yours sincerely

A handwritten signature in black ink, appearing to read "Karen Adams", written over a light blue horizontal line.

Karen Adams
Vice President Finance and Company Secretary